Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Jul 31, 2026 → Mar 31, 2027
See other at-risk trials from Shanghai Zhongshan Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 31, 2026 to Mar 31, 2027 Show 6 more changesShow less
    • Recruitment opened
    • Study completion pushed from Jul 31, 2026 to Jul 31, 2027
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 1, 2025 to Jun 20, 2025
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 1 of 3 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.
Trial Details
NCT Number NCT07012980
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Hoffmann-La Roche, BeiGene
Conditions
(from sponsor)		 Diffuse Large B-Cell Lymphoma
Related terms Lymphoma, Large B-Cell, Diffuse
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov